Skip to main content
Erschienen in: Journal of Neural Transmission 9/2018

26.06.2018 | Neurology and Preclinical Neurological Studies - Original Article

Comparing incobotulinumtoxinA (Xeomin®) and onabotulinumtoxinA (Botox®): identical potency labelling in the hemidiaphragm assay

verfasst von: Dirk Dressler, Lizhen Pan, Hans Bigalke

Erschienen in: Journal of Neural Transmission | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Botulinum toxin (BT) is provided by several manufacturers producing a number of different drugs. Their potency is given in internationally standardised mouse units (MU). Clinical practise, however, reveals that the potency labelling of different BT drugs may not be identical. We wanted to use the mouse diaphragm assay (MDA) to compare the two BT drugs onabotulinumtoxinA (ONA) and incobotulinumtoxinA (INCO). For this, we measured the paresis time (PT) of different ONA or INCO doses. All BT came from several different and unexpired drug batches. PT for 20MU were 169.7 ± 28.9 min (ONA) and 132.3 ± 1.5 min (INCO) (p = 0.089), for 60MU 105.3 ± 10.1 min and 84.7 ± 4.2 min (p = 0.031), for 100MU 69.7 ± 1.5 min and 66.0 ± 7.0 min (p = 0.462) and for 140MU 74.7 ± 0.6 min and 62.3 ± 2.1 min (p = 0.100), respectively. The overall PT were 104.8 ± 12.5 and 86.3 ± 8.5 min (p = 0.178). Results presented here do not reveal differences in potency labelling between ONA and INCO, even when the full range of therapeutic doses are examined, although there was a trend towards stronger INCO effects. Data confirm previous reports on identical potency labelling of ONA and INCO. The MDA seems to be an appropriate instrument to test the potency labelling of other BT drugs as well, including new BT drugs currently under development.
Literatur
Zurück zum Zitat Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949–1951CrossRefPubMed Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949–1951CrossRefPubMed
Zurück zum Zitat Buelbring E (1946) Observation on the isolated phrenic nerve diaphragm preparation in the rat. Br J Pharmacol 1:38–61 Buelbring E (1946) Observation on the isolated phrenic nerve diaphragm preparation in the rat. Br J Pharmacol 1:38–61
Zurück zum Zitat Dressler D (2009) Routine use of Xeomin® in patients pre-treated with Botox®. Eur J Neurol 16(Suppl 2):2–5CrossRefPubMed Dressler D (2009) Routine use of Xeomin® in patients pre-treated with Botox®. Eur J Neurol 16(Suppl 2):2–5CrossRefPubMed
Zurück zum Zitat Dressler D (2010) Comparing Botox® and Xeomin® for the treatment of axillar hyperhidrosis. J Neural Transm 117:317–319CrossRefPubMed Dressler D (2010) Comparing Botox® and Xeomin® for the treatment of axillar hyperhidrosis. J Neural Transm 117:317–319CrossRefPubMed
Zurück zum Zitat Dressler D (2012) Five-year experience with incobotulinumtoxinA (Xeomin®): the first botulinum toxin drug free of complexing proteins. Eur J Neurol 19:385–389CrossRefPubMed Dressler D (2012) Five-year experience with incobotulinumtoxinA (Xeomin®): the first botulinum toxin drug free of complexing proteins. Eur J Neurol 19:385–389CrossRefPubMed
Zurück zum Zitat Dressler D, Bigalke H (2016) Comparing incobotulinumtoxina (Xeomin) and onabotulinumtoxina (Botox): identical potency labeling in the hemidiaphragm assay. Toxicon 123:S23 Dressler D, Bigalke H (2016) Comparing incobotulinumtoxina (Xeomin) and onabotulinumtoxina (Botox): identical potency labeling in the hemidiaphragm assay. Toxicon 123:S23
Zurück zum Zitat Dressler D, Mander G, Fink K (2012) Measuring the potency labelling of onabotulinumtoxinA (Botox®) and Xeomin® in an LD50 assay. J Neural Transm 119:13–15CrossRefPubMed Dressler D, Mander G, Fink K (2012) Measuring the potency labelling of onabotulinumtoxinA (Botox®) and Xeomin® in an LD50 assay. J Neural Transm 119:13–15CrossRefPubMed
Zurück zum Zitat Dressler D, Tacik P, Adib Saberi F (2014) Botulinum toxin therapy of cervical dystonia: comparing Botox® and Xeomin®. J Neural Transm 121:29–31CrossRefPubMed Dressler D, Tacik P, Adib Saberi F (2014) Botulinum toxin therapy of cervical dystonia: comparing Botox® and Xeomin®. J Neural Transm 121:29–31CrossRefPubMed
Zurück zum Zitat European Pharmacopoeia 6.0 (2008a) Botulinum toxin type A for injection 1327–1329 European Pharmacopoeia 6.0 (2008a) Botulinum toxin type A for injection 1327–1329
Zurück zum Zitat European Pharmacopoeia 6.0 (2008b) Statistical analysis of biological assays and tests. 5.3: 571–600 European Pharmacopoeia 6.0 (2008b) Statistical analysis of biological assays and tests. 5.3: 571–600
Zurück zum Zitat Goeschel H, Wohlfahrt K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin: neutralizing and nonneutralizing antibodies—therapeutic consequences. Exp Neurol 147:96–102CrossRef Goeschel H, Wohlfahrt K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin: neutralizing and nonneutralizing antibodies—therapeutic consequences. Exp Neurol 147:96–102CrossRef
Zurück zum Zitat Hunt T, Clarke K (2009) Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A. Clin Neuropharmacol 32:28–31CrossRefPubMed Hunt T, Clarke K (2009) Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A. Clin Neuropharmacol 32:28–31CrossRefPubMed
Zurück zum Zitat Kranz G, Haubenberger D, Voller B, Posch M, Schnider P, Auff E, Sycha T (2009) Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study. Mov Disord 24:231–236CrossRefPubMed Kranz G, Haubenberger D, Voller B, Posch M, Schnider P, Auff E, Sycha T (2009) Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study. Mov Disord 24:231–236CrossRefPubMed
Zurück zum Zitat Marion MH, Sheehy M, Sangla S, Soulayrol S (1995) Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiat 59:102–103CrossRefPubMed Marion MH, Sheehy M, Sangla S, Soulayrol S (1995) Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiat 59:102–103CrossRefPubMed
Zurück zum Zitat Pearce LB, Borodic GE, First ER, MacCallum RD (1994) Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol 128:69–77CrossRefPubMed Pearce LB, Borodic GE, First ER, MacCallum RD (1994) Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol 128:69–77CrossRefPubMed
Zurück zum Zitat Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M (2002) Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 72:459–462PubMedPubMedCentral Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M (2002) Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 72:459–462PubMedPubMedCentral
Zurück zum Zitat Roggenkämper P, Jost WH, Bihari K, Comes G, Grafe S, For the NT 201 Blepharospasm Study Team (2006) Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 113:303–312CrossRefPubMed Roggenkämper P, Jost WH, Bihari K, Comes G, Grafe S, For the NT 201 Blepharospasm Study Team (2006) Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 113:303–312CrossRefPubMed
Zurück zum Zitat Van den Bergh P, Lison D, Dose standardisation of BTX (1996) 3rd International Dystonia Symposium, October 9–11, 1996, Miami, Florida. Affiliated National Dystonia Associations, Chicago, Illinois, p 30 Van den Bergh P, Lison D, Dose standardisation of BTX (1996) 3rd International Dystonia Symposium, October 9–11, 1996, Miami, Florida. Affiliated National Dystonia Associations, Chicago, Illinois, p 30
Zurück zum Zitat Wohlfarth K, Schwandt I, Wegner F, Jürgens T, Gelbrich G, Wagner A, Bogdahn U, Schulte-Mattler W (2009) Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers. A double-blind, randomized, dose-ranging study. J Neurol 256:1201–1201CrossRef Wohlfarth K, Schwandt I, Wegner F, Jürgens T, Gelbrich G, Wagner A, Bogdahn U, Schulte-Mattler W (2009) Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers. A double-blind, randomized, dose-ranging study. J Neurol 256:1201–1201CrossRef
Metadaten
Titel
Comparing incobotulinumtoxinA (Xeomin®) and onabotulinumtoxinA (Botox®): identical potency labelling in the hemidiaphragm assay
verfasst von
Dirk Dressler
Lizhen Pan
Hans Bigalke
Publikationsdatum
26.06.2018
Verlag
Springer Vienna
Erschienen in
Journal of Neural Transmission / Ausgabe 9/2018
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-018-1897-x

Weitere Artikel der Ausgabe 9/2018

Journal of Neural Transmission 9/2018 Zur Ausgabe

Neurology and Preclinical Neurological Studies - Original Article

Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy

Neurology and Preclinical Neurological Studies - Original Article

Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson’s disease

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.